EyePoint, CoreWeave and Eos Energy shares slide to 52-week lows

what happened

On Monday, shares of EyePoint Pharmaceuticals (EYPT), CoreWeave (CRWV) and Eos Energy Enterprises (EOSE) reached new 52-week lows, according to Stocktwits. EyePoint led the decline, sinking 85% to a record low near $0.40 after its LUCIA study, the second pivotal Phase 3 trial of DURAVYU for wet age-related macular degeneration, showed the drug did not match aflibercept in preserving vision at weeks 52 and 56.

The company plans to cut 53% of its staff, a step it expects to save $30 million a year at a cost of about $9 million in severance. As of September 30 it held roughly $118 million in cash and equivalents, and it will direct the remaining resources to Phase 3 work in diabetic macular edema. CoreWeave slipped 0.4% to an annual low of $59.25 after BNP Paribas cut its target to $117 from $169 while keeping an Outperform rating, and MoffettNathanson lowered its target to $89 from $107 with a Neutral rating. Analysts flagged risks from weaker investor confidence and costly financing tied to its debt obligations.

Eos Energy fell 0.5% to a two-year low of $1.72. Preliminary third-quarter revenue of $82 million to $83 million, up 19% to 21% from the prior quarter, was overshadowed by guidance that puts 2026 revenue in the lower half of the $300 million to $350 million range, the second reduction after August. Year to date, the three stocks are down between 14% and 97%.

why it matters

The moves are company-specific, but they show investors punishing failed trials, funding risk and lowered forecasts. Retail sentiment on Stocktwits diverged: EyePoint and CoreWeave turned extremely bullish, while Eos remained bearish. These readings reflect retail traders rather than institutional positioning.

market impact

Biotech, AI cloud and battery storage small caps: pressure from weak trial data, financing risk and guidance cuts.

tags

instruments